At Aquila, we use FoxP3+ regulatory T cell (Treg) suppression assays to assess the ability of your compound to either boost or reduce Treg activity. Tregs can inhibit unwanted immunity e.g. autoimmune disease but conversely can suppress desirable immunity in cancer.
We can measure the proliferative capacity of effector T cells (Teffs) with high-throughput flow cytometry, as well as a range of key assay readouts. These include ELISA and/or multiplex to measure cytokine expression (e.g. IFN-γ, IL-2).
To further our service offering, we can generate induced FoxP3+ Tregs (iTregs) as well as isolate ‘natural’ Tregs (nTregs), and are working towards incorporating these cell types into our Treg suppression assay. This may more closely reflect the FoxP3-induction believed to be driven by some tumours, thereby improving our capacity to model the tumour microenvironment (TME).
Please get in touch to learn more about our human Treg assays.